Demonstrates that fermented okara enhances immune responses in mice, suggesting its potential in cancer therapy.
Okara, a byproduct of soybean processing, can be valorized through microbial fermentation to yield bioactive compounds. In this study, we used Lacticaseibacillus paracasei , a Gram-positive lactic acid bacterium commonly applied in probiotic and dairy fermentations, to perform solid-state fermentation of okara. Crude polysaccharides were then purified using DEAE Sepharose Fast Flow and BioGel P-2 gel filtration chromatography, yielding a high-purity β -1,4-galactan polysaccharide fraction (LPP-A) with an average molecular weight of 6 kDa. To assess its immunostimulatory potential, LPP-A was evaluated as an adjuvant in a murine vaccination model with ovalbumin (OVA) as the antigen. Mice immunized with OVA plus LPP-A induced robust OVA-specific cytotoxic T lymphocyte (CTL) responses and high IgG antibody titers, indicating the induction of strong antigen-specific cellular and humoral responses. In a subsequent tumor challenge, the OVA plus LPP-A group showed significantly inhibited EG7-OVA tumor growth, suggesting high potential for LPP-A as an immune-enhancing adjuvant for cancer immunotherapy. These results demonstrate that fermenting okara can produce a β -1,4-galactan (LPP-A) with potent vaccine adjuvant properties, supporting its value in protein-based immunization strategies. Fermentation of okara by Lacticaseibacillus paracasei produced a 6 kDa β -1,4-galactan (LPP-A). As an adjuvant, LPP-A enhanced OVA-specific CTL and IgG responses, suppressed tumor growth in mice, and demonstrated potential for cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: